quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·141d
PRRelease
Nexalin Technology Inc. logo

Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer's Disease Program

NXL· Nexalin Technology Inc.
Health Care
Original source

Companies

  • NXL
    Nexalin Technology Inc.
    Health Care

Related

  • SEC1d
    Nexalin Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
  • PR8d
    Nexalin Advances FDA Alzheimer's Strategy Following Landmark Leadership Meetings in the U.S. and China
  • PR9d
    Join Nexalin's Exclusive Live Investor Webinar and Q&A Session on April 21
  • PR14d
    Nexalin Announces Peer-Reviewed Study Showing the Company's DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents
  • SEC29d
    SEC Form 10-K filed by Nexalin Technology Inc.
  • SEC57d
    Nexalin Technology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
  • PR58d
    Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market
  • PR59d
    Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022